Based solely on their expression levels, it can be considered that Abs targeting FcRH5 might be more effective against CD34+ MM cells compared to CD34− MM cells, while those targeting GPRC5D might be less effective for this cell population. The gene discussed is FCRL5; the disease is Miyoshi myopathy.